Kodiak Sciences Inc (KOD): Price and Financial Metrics

Kodiak Sciences Inc (KOD): $1.95

0.04 (-2.01%)

POWR Rating

Component Grades








Add KOD to Watchlist
Sign Up

Industry: Biotech




#283 of 359

in industry

KOD Price/Volume Stats

Current price $1.95 52-week high $9.80
Prev. close $1.99 52-week low $1.95
Day low $1.95 Volume 483,600
Day high $2.02 Avg. volume 689,853
50-day MA $3.12 Dividend yield N/A
200-day MA $5.76 Market Cap 102.28M

KOD Stock Price Chart Interactive Chart >

Kodiak Sciences Inc (KOD) Company Bio

Kodiak Sciences is a clinical stage biopharma specializing in therapeutics to treat chronic retinal diseases. The company was founded in 2005 and is based in New York City, New York.

KOD Latest News Stream

Event/Time News Detail
Loading, please wait...

KOD Latest Social Stream

Loading social stream, please wait...

View Full KOD Social Stream

Latest KOD News From Around the Web

Below are the latest news stories about KODIAK SCIENCES INC that investors may wish to consider to help them evaluate KOD as an investment opportunity.

Kodiak Sciences Inc. (KOD) Down 19.9% Since Last Earnings Report: Can It Rebound?

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | September 13, 2023

Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY on Wednesday, September 13, 2023, at 12:55 p.m. Eastern Time.

Yahoo | September 8, 2023

New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion

Kodiak Sciences Inc. (NASDAQ: KOD) today announced top-line, one-year (48 weeks) results for its ABC Platform based investigational therapy tarcocimab tedromer 5 mg from the pivotal BEACON study in patients with macular edema due to retinal vein occlusion (RVO).

Yahoo | September 7, 2023

Owning 49% shares,institutional owners seem interested in Kodiak Sciences Inc. (NASDAQ:KOD),

Key Insights Given the large stake in the stock by institutions, Kodiak Sciences' stock price might be vulnerable to...

Yahoo | September 5, 2023

Kodiak (KOD) Q2 Earnings Miss, New Lead Candidate in Focus

Kodiak (KOD) reports weaker-than-expected results in second-quarter 2023. The company also provides an update on the status of its pipeline after discontinuing the tarcocimab program.

Yahoo | August 16, 2023

Read More 'KOD' Stories Here

KOD Price Returns

1-mo -13.72%
3-mo -73.07%
6-mo -60.45%
1-year -75.56%
3-year -81.39%
5-year N/A
YTD -72.77%
2022 -57.77%
2021 -42.29%
2020 104.18%
2019 913.38%
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!